GLP-1 and Perimenopausal Weight: The Still-Cycling Years

The change is real — and the scale is the wrong instrument for it

This guide is for the transition years: perimenopause, when you're often still cycling (however irregularly), possibly curious about hormone therapy, and, importantly, still able to get pregnant. (If your periods have fully stopped, our companion on GLP-1s after menopause covers the post-menopausal visceral-fat and heart-risk picture instead.)

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

The Study of Women's Health Across the Nation followed women through the transition with DXA body-composition scans. Fat and lean mass both increased before it began. At its start, the rate of fat gain doubled and lean mass began to decline, and both trajectories continued until two years after the final menstrual period, then flattened¹.

Then comes the finding that almost nobody repeats. In the same cohort, body weight climbed linearly through premenopause with no acceleration at the transition at all — its trajectory simply went flat afterwards¹. The authors' conclusion is precise: accelerated fat gain and lean-mass loss are transition-related phenomena, while the rate of weight gain is not.

That matters if you are standing on a bathroom scale in your forties wondering what changed. What the transition alters is the composition of the weight, not the speed at which it arrives. "Same habits, clothes fit differently, scale barely moved" is not a contradiction — it is the documented pattern.

And it moves to the middle, measurably

A second SWAN analysis followed 380 women with regional DXA over a median 11.8 years and quantified where the fat goes. In the white referent group:

Central fat accumulation more than quadrupled its rate at the transition, and visceral and gynoid fat only began rising then². The waist row is the one worth noticing: waist girth grew throughout, and the three rates were not statistically different from one another. The authors conclude that the transition is associated with the development of central adiposity, and that waist or hip circumference are less sensitive to changes in fat distribution than imaging is². A tape measure will under-report what is happening to you.

What the GLP-1 evidence covers, and what it doesn't

These are the drugs that act on fat storage and insulin handling, so the interest is reasonable. In STEP 1, 1,961 adults with overweight or obesity and without diabetes lost a mean 14.9% of body weight on once-weekly semaglutide 2.4 mg over 68 weeks versus 2.4% on placebo³. In SURMOUNT-1, 2,539 adults lost a mean 20.9% on tirzepatide 15 mg over 72 weeks versus 3.1% on placebo⁴.

Those headline trial averages do not isolate the menopause transition. There is stage-specific evidence: a later post hoc analysis of women in the SURMOUNT program examined tirzepatide response by reproductive stage and found weight reduction across stages⁸. That analysis was manufacturer-funded and done after the trials, so it does not establish a treatment protocol for perimenopause. A review dedicated to this population also describes limited evidence and calls for further research into benefits, risks and appropriate use⁵.

So the honest reading is that these drugs work in women of this age. How the hormonal transition affects an individual response remains uncertain; subgroup findings are more informative than an absence of data, but less definitive than a trial designed around that question.

The caveat that belongs only to the still-cycling years

Pregnancy remains possible in early perimenopause, which makes contraception a live clinical question here in a way it stops being later — and there is a labeled interaction that catches people out. Zepbound's prescribing information, read on DailyMed (label version dated 6 May 2026), states that tirzepatide "may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying," that the delay is largest after the first dose and diminishes over time, and that patients on oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation⁶.

Semaglutide's label carries no contraceptive instruction of any kind; its drug-interactions section reports that semaglutide 1 mg once weekly did not affect the absorption of orally administered medications⁷. Two drugs, two different rules — which is a genuine reason the molecule choice is not interchangeable at this stage of life. Our guide to GLP-1s and birth control walks through the practical version.

Because perimenopause layers hormonal symptoms on top of metabolic ones, this is a stage where oversight and labs matter more, not less. Talk to a clinician who will check thyroid and glucose markers, ask where you actually are in the transition, and coordinate with whoever manages any hormone therapy — that is worth more than the cheapest sticker price. Optimized Health, a concierge weight-loss and hormone clinic with lab-guided dosing, is one worked example of that kind of oversight — though its own homepage overstates the point by calling its compounded semaglutide and tirzepatide "FDA-approved," which they are not, and its telehealth footprint is limited to five states.

Where this sits on the evidence scale

The body-composition change: strong. Longitudinal DXA in a large multi-ethnic cohort, with two independent analyses agreeing, and a counterintuitive negative result (no acceleration in weight) that argues the measurement was honest rather than confirmatory.

GLP-1 efficacy at this age: strong, but borrowed. Large placebo-controlled trials with unambiguous results — in populations defined by BMI, not by where anyone was in the transition.

Whether perimenopause changes the response: limited stage-specific evidence. A post hoc SURMOUNT analysis offers useful reproductive-stage results⁸, while dedicated reviews still call for stronger research⁵. Those findings do not validate every program marketed as a “perimenopause protocol.”

The contraceptive interaction: labeled and specific, which puts it on firmer ground than most of the rest of this page. To weigh the two molecules against each other, read semaglutide vs tirzepatide for mothers.